Continued Treatment with Tirzepatide for Maintenance of Weight Reduction in Adults with Obesity (SURMOUNT-4)

Background

SURMOUNT-4 was designed to answer a critical clinical question that parallels STEP 4 for semaglutide: is continued tirzepatide treatment necessary to maintain weight loss after initial successful weight reduction, or can treatment be discontinued after achieving goal weight?

The trial directly assessed the biological requirement for ongoing GIP/GLP-1 receptor co-activation in weight maintenance. Given that obesity involves persistent dysregulation of appetite-regulating hormones, adipokines, and energy expenditure set points — not merely a behavioral deficit — the expectation was that withdrawal of pharmacological support would result in physiological compensation and weight regain. SURMOUNT-4 provided the empirical evidence for this hypothesis.

Methods

Design: Randomized, double-blind, placebo-controlled withdrawal trial

Phase 1 — Lead-in (Weeks 0–36): All 670 participants received open-label tirzepatide 10 mg or 15 mg weekly for 36 weeks

Phase 2 — Maintenance (Weeks 36–88): Participants who completed the lead-in were randomized 1:1 to:

• Continue tirzepatide at the same dose (n=335)
• Switch to placebo (n=335)

Population: 670 adults with obesity (BMI ≥30 kg/m²) or overweight (BMI ≥27) with ≥1 weight-related comorbidity; no T2D

Primary endpoint: Percent change in body weight from Week 36 to Week 88

Key Findings

Phase 1 Lead-In (Weeks 0–36):

• Mean weight loss on tirzepatide during 36-week lead-in: −20.9%
• 96% of participants completed the lead-in phase and were randomized
• Baseline BMI before lead-in: mean 38.0 kg/m²

Phase 2 Maintenance (Week 36 → Week 88):

• Placebo arm regained 14.8% of body weight — effectively erasing two-thirds of the lead-in benefit
• Continued tirzepatide arm achieved an additional 5.5% weight loss beyond the 20.9% lead-in loss — demonstrating that the obesity pharmacotherapy window extends beyond initial weight loss
• Total weight loss of 25.8% from baseline represents outcomes approaching major bariatric surgical procedures

Cardiometabolic Preservation (W36→88):

• Cardiometabolic improvements achieved during lead-in were substantially reversed upon withdrawal — confirming that the benefits are medication-dependent, not permanently established

Safety (Maintenance Phase):

• Adverse event profile comparable between groups during maintenance (most GI events had resolved during lead-in dose-escalation)
• No new safety signals during 52-week maintenance period
• Injection site reactions rare in both groups at maintenance

Comparison with STEP 4 (Semaglutide)

The parallel design of SURMOUNT-4 and STEP 4 allows a mechanistic comparison:

Tirzepatide produced nearly double the initial weight loss of semaglutide during lead-in, reflecting the dual GIP/GLP-1 mechanism advantage. Both trials demonstrate identical qualitative conclusions: pharmacological withdrawal results in substantial weight regain regardless of the agent, confirming that obesity requires chronic treatment.

Mechanism of Pharmacological Weight Maintenance

The weight regain after tirzepatide withdrawal reflects the physiological response to reduced pharmacological signaling:

1. Appetite restoration: GIP and GLP-1 receptor signaling in hypothalamic satiety centers is withdrawn; homeostatic hunger signaling (ghrelin, NPY/AgRP) rebounds to compensatory levels
2. Energy expenditure reduction: GH/metabolic rate effects of the GLP-1 axis normalize; adaptive thermogenesis that accompanies significant weight loss intensifies without pharmacological counter-signaling
3. Adipokine rebound: Leptin resistance and adipokine dysregulation that characterize obesity partially return as fat mass re-accumulates
4. Set-point defense: The biological set point for body fat is not permanently reset by pharmacological weight loss — ongoing pharmacological suppression is required to maintain a lower defended weight

Clinical Significance

1. Chronic treatment paradigm confirmed: SURMOUNT-4 definitively establishes that obesity treated with tirzepatide requires indefinite continuation — analogous to antihypertensive or statin therapy for cardiovascular risk reduction
2. 25%+ weight loss achievable: Continuing tirzepatide beyond initial weight loss goals achieves total weight reductions (−25.8%) approaching laparoscopic sleeve gastrectomy outcomes without surgery
3. Cardiometabolic benefit requires ongoing treatment: The reversal of BP, glucose, and lipid improvements upon withdrawal reinforces that stopping therapy risks cardiovascular risk factor deterioration beyond weight regain alone
4. Policy and access implications: SURMOUNT-4 data directly supports payer coverage for long-term tirzepatide maintenance — the clinical case for indefinite treatment is now empirically established

Limitations

• Withdrawal design: placebo arm had 36 weeks of tirzepatide pre-randomization — not a treatment-naive control; confounders from pre-existing weight loss state affect the comparison
• Selection bias: only participants who tolerated tirzepatide and completed the 36-week lead-in were randomized; non-responders and intolerant patients excluded
• 52-week maintenance phase; very long-term weight trajectories beyond this window not established
• No T2D patients in this trial; metabolic maintenance effects in diabetic populations assessed separately in SURMOUNT-2 extension data
• Cost and access barriers may limit real-world ability to continue chronic tirzepatide therapy as SURMOUNT-4 recommends